peptide quality FAQ

Yes, but adjust your dosing. A 96.8% pure peptide means 3.2% of the powder is impurities or inactive material. If you ordered 5mg and dose based on 100% purity, you're actually administering 4.84mg of active peptide per vial. For single-dose protocols, this difference is negligible. For multi-week studies where cumulative dose matters, recalculate based on the actual purity. Multiply your target dose by 0.968 to determine the correct administration amount. Research-grade protocols prefer ≥98% specifically to avoid this math.

Verify your peptide's pH stability range. Some peptides tolerate 5.0–7.0 (the full BAC water specification), while others require tighter control. If your protocol specifies 6.0–7.0 and the COA shows 5.2, the water is out of spec for your application even though it meets general BAC water standards. In this scenario, source water with confirmed pH ≥6.0 or contact the peptide manufacturer for pH compatibility clarification. Tirzepatide and semaglutide both tolerate 5.0–7.0. But CJC-1295 and certain acetate-salt peptides degrade rapidly below pH 6.0.

Reject the vial. A 2-Dalton discrepancy suggests either a synthesis error (wrong amino acid incorporated) or contamination with a structurally similar peptide. Mass spec tolerance for research-grade peptides is ±1 Da maximum. Beyond that, you're not using the compound you think you are. This isn't a purity issue (HPLC might still show 99%). It's an identity failure. Contact the supplier for a replacement batch with correct MS confirmation before proceeding.

Trust the COA, not the label. Labels are printed in advance and applied during packaging. The COA is generated after testing the actual batch. If there's a mismatch, the COA value is correct. This happens when production lots are split into different fill sizes but the wrong labels are applied. Reconstitute based on the COA concentration to avoid 2× overdosing. We've seen this exact error cause researchers to double their intended dose for an entire study phase.

Do not use the water. Pending results mean testing is incomplete. Endotoxin testing via LAL assay takes 24–48 hours under standard protocols, so 'pending' status indicates either the batch was released prematurely or testing hasn't been performed. Contact the supplier for completed results before reconstituting any peptide. Our team has seen researchers use 'pending' water assuming it would retroactively pass. In three documented cases, final results exceeded 0.5 EU/mL, meaning all reconstituted peptides from those batches were contaminated.

Bacteriostatic water has a shelf life. Typically 28 days after opening and up to 24 months unopened when stored at 20–25°C. If the COA is more than 12 months old, verify the vial's expiration date printed on the label. An old COA with a current expiration date is acceptable. The COA documents the batch at manufacturing, not at your purchase date. If the expiration date is missing or illegible, contact the supplier for confirmation. Expired bacteriostatic water loses preservative efficacy. Benzyl alcohol concentration drops below 0.9% w/v, which allows microbial growth even in a previously sterile vial.

Use the peptide within 72 hours and refrigerate it continuously at 2–8°C between doses. After 72 hours, bacterial contamination risk escalates significantly. Discard the vial rather than risk injecting a solution with bacterial colony counts above safe thresholds. Do not attempt to add BAC Water to an already-reconstituted vial to extend its lifespan. Benzyl alcohol inhibits bacterial reproduction; it does not kill existing bacteria. Mixing solvents also changes the final benzyl alcohol concentration in unpredictable ways, which can either under-preserve (too dilute) or cause injection site irritation (too concentrated). For the next reconstitution, use BAC Water from the start.

Discard the vial immediately and do not inject it. Cloudiness, floating particles, or color change all indicate contamination or chemical breakdown. Peptides in solution should be completely transparent and colorless. If the solution looks different from the day it was reconstituted, the peptide is no longer safe to use. Cloudiness specifically suggests bacterial growth or peptide aggregation, both of which render the solution non-viable. Visible contamination means the bacterial load exceeded the point where benzyl alcohol could inhibit reproduction, which happens when reconstitution technique introduced high initial contamination or when storage temperature exceeded refrigeration range for extended periods.

Discard it. The 28-day bacteriostatic window applies to the BAC Water vial itself, not just the reconstituted peptide. After 28 days, benzyl alcohol degradation reduces bacteriostatic efficacy, and repeated needle punctures increase contamination load beyond what the remaining preservative can inhibit. Date every BAC Water vial the first time you puncture the stopper. Not the manufacturing date or the date you received it, but the date of first use. A 30mL vial accessed twice weekly lasts 8–10 weeks in terms of volume but only four weeks in terms of sterile integrity. Plan peptide reconstitution schedules to consume BAC Water within the 28-day window.

BAC Water works identically at all reconstitution volumes. Melanotan 2 and PT-141 are often reconstituted at higher dilutions (3–5mL per 10mg vial) to allow more precise dosing with standard insulin syringes. The benzyl alcohol concentration remains 0.9% regardless of how much BAC Water you add to the peptide vial. The preservative is already in the solvent, not something you dose separately. Larger reconstitution volumes do not dilute bacteriostatic protection. The 28-day viability window applies equally to a 2mg vial reconstituted with 1mL as it does to a 10mg vial reconstituted with 5mL.

Do not use the peptide. A +1.2 Da error suggests either an amino acid substitution or incomplete reduction of a disulphide bond. Contact the supplier for a corrected synthesis or request mass spec/MS analysis to identify the modification. Without fragmentation data, you can't confirm the peptide's sequence integrity.

Request the full HPLC chromatogram and examine the minor peak pattern. If multiple minor peaks appear at retention times close to the main peak, deletion sequences or incomplete deprotection products are present. These can compete for receptor binding or alter pharmacokinetics without dramatically affecting purity percentage. A peptide with 96% purity from one dominant impurity behaves more predictably than 96% purity from six different impurities at 0.5–1% each. If the vendor can't provide chromatogram images, assume quality documentation is incomplete and source from a supplier that performs full vip comparative studies on every batch.

Multiple mass spec peaks indicate a heterogeneous sample. Typically deletion sequences, truncation products, or oxidation variants. The dominant peak should match your target peptide's calculated mass; secondary peaks 14–16 Da higher suggest methionine oxidation (common during synthesis), while peaks 1–2 amino acid masses lower indicate deletion sequences. If secondary peaks represent more than 5% of total ion current, the peptide doesn't meet research-grade standards. For critical experiments, request re-synthesis or switch suppliers rather than attempting to use a chemically impure preparation.

Run side-by-side receptor binding assays or functional assays using identical protocols and fresh reconstitutions from both suppliers. Differences in EC50 values greater than 2-fold suggest purity or potency differences the COAs didn't capture. If both peptides show similar activity but one costs significantly less, examine the minor peak profiles in their HPLC traces. Cheaper synthesis often tolerates higher impurity levels that don't affect simple binding assays but may confound long-term stability studies. Our team routinely tests samples from multiple batches before committing to large-volume orders; the upfront cost of comparative testing is negligible compared to months of compromised experimental data.

Verify batch consistency first. Run HPLC on samples from different vials within the same lot. Inconsistent purity across vials within a single batch indicates synthesis process variability or improper lyophilization. If within-batch purity varies by more than 2%, the issue is manufacturing control. If purity is consistent but results still don't replicate, the next variable is reconstitution protocol. Peptides reconstituted in incorrect solvents or at wrong pH can form aggregates that alter bioavailability without changing visual appearance.

Request them before placing another order. A legitimate supplier provides HPLC and mass spectrometry data as standard documentation, not premium add-ons. If they cite 'proprietary methods' or 'internal testing only', that's a verification gap you can't audit. The alternative: source from a supplier who includes third-party test results with every shipment. For peptide-based studies heading to publication, reviewers will request this data during manuscript review. Securing it upfront prevents re-running experiments with properly documented compounds later.

Contact the supplier immediately and request re-testing before reconstituting the peptide. Lyophilized peptides that experienced heat exposure may appear visually identical but have undergone partial denaturation. The only reliable confirmation is re-running HPLC to compare current purity against the original Certificate of Analysis. Most research-grade suppliers include time-temperature indicators in shipments precisely to catch this. If yours doesn't, request it as standard for future orders.

'ND' (Not Detected) without a stated detection limit is unacceptable. It could mean <0.001 EU/mg or <10 EU/mg depending on assay sensitivity. Request a quantitative LAL result with the detection limit explicitly stated. For in vivo studies or primary immune cell work, insist on <0.1 EU/mg confirmed via LAL Kinetic Chromogenic method.

Request a replacement batch. Multiple secondary peaks above 2% indicate incomplete synthesis or significant degradation products that will interfere with assay performance. The 97% purity number is misleading when impurities consist of truncated analogs that bind the same target receptor with altered affinity, skewing dose-response curves. Peptides with this chromatogram profile produce irreproducible results across replicates.

Incomplete solubility indicates aggregation, often caused by temperature excursion during shipping or oxidation during storage. Aggregated peptides can't be rescued. Heating, sonication, or pH adjustment won't restore monomeric structure. Discard the vial and request a replacement. If the supplier blames your reconstitution technique, that's a deflection. Properly stored peptides dissolve completely in the specified solvent at the stated concentration.